Radiopharm Theranostics' RAD202 Advances to Phase 1 Cohort 3 with Positive Safety Recommendation
RADX sits 28% above its 52-week low of $3.496.
Summary
Radiopharm Theranostics announced its 177Lu-RAD202 (RAD202) asset has advanced to Cohort 3 in its Phase 1 'HEAT' clinical trial for HER2-positive advanced solid tumors. This progression follows a positive recommendation from the Data Safety and Monitoring Committee (DSMC), allowing dose escalation to 130mCi. This news highlights continued clinical development for Radiopharm, following recent announcements regarding other pipeline assets like RAD 402 and RAD 101. For a small-cap biopharmaceutical company, advancing a drug in an early-stage clinical trial, especially with a positive safety review, is a significant de-risking event. It indicates the drug is well-tolerated at initial doses and moves it closer to potential efficacy studies. Investors will now monitor further updates on the Phase 1 dose escalation, with the company aiming to complete this phase by the end of 2026.
At the time of this announcement, RADX was trading at $4.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.4M. The 52-week trading range was $3.50 to $16.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.